The U.S. Food and Drug Administration (FDA) has approved a groundbreaking gene therapy for individuals suffering from recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe Rare Skin Disorder.This treatment, known as prademagene zamikeracel or pz-cel, will be marketed under the brand name Zevaskyn. It is the first and only FDA-approved therapy for RDEB and brings new hop... https://healthcare360magazine.com/gene-therapy-for-rare-skin-disorder/